Abstract：
UNASSIGNED: Near-fatal asthma (NFA) is a severe condition that can lead to respiratory arrest or high carbon dioxide levels, often requiring mechanical ventilation. Biologics have revolutionized the management of severe asthma, significantly improving symptom severity, reducing the number of exacerbations and hospitalizations, and decreasing the need for oral corticosteroids. However, their effectiveness in acute settings, particularly for ICU patients experiencing severe respiratory failure, is not well-studied. More research is needed to determine if biologics can improve recovery during severe asthma exacerbations.
UNASSIGNED: We report a case of NFA in a patient with severe allergic eosinophilic asthma, who experienced global respiratory failure necessitating hospitalization, intubation, and veno-venous extracorporeal membrane oxygenation (VV-ECMO). Given the severity of the clinical condition, compassionate administration of Benralizumab, which targets the IL-5 receptor, was attempted.
UNASSIGNED: Five days from anti-IL5 receptor treatment start, the patient was extubated and the ECMO stopped. After the stepdown to the respiratory intensive care unit (RICU), the patient was weaned from oxygen therapy and subsequently discharged from hospital.
UNASSIGNED: Benralizumab demonstrated rapid effectiveness in improving respiratory failure leading to successful weaning from VV-ECMO and subsequent extubation.
UNASSIGNED: We report a case of NFA in a patient with severe allergic eosinophilic asthma, who experienced global respiratory failure necessitating hospitalization, intubation, and veno-venous extracorporeal membrane oxygenation (VV-ECMO). Given the severity of the clinical condition, compassionate administration of Benralizumab, which targets the IL-5 receptor, was attempted.
UNASSIGNED: Five days from anti-IL5 receptor treatment start, the patient was extubated and the ECMO stopped. After the stepdown to the respiratory intensive care unit (RICU), the patient was weaned from oxygen therapy and subsequently discharged from hospital.
UNASSIGNED: Benralizumab demonstrated rapid effectiveness in improving respiratory failure leading to successful weaning from VV-ECMO and subsequent extubation.
摘要：
■近致命性哮喘（NFA）是一种严重的疾病，可导致呼吸停止或二氧化碳水平升高，通常需要机械通风。生物制剂彻底改变了严重哮喘的管理，显着改善症状严重程度，减少恶化和住院的次数，减少对口服皮质类固醇的需求。然而,它们在急性环境中的有效性，特别是对于ICU严重呼吸衰竭的患者，没有得到很好的研究。需要更多的研究来确定生物制剂是否可以改善严重哮喘发作期间的恢复。病例研究：我们报告了一例严重过敏性嗜酸性粒细胞性哮喘患者的NFA，经历了全球呼吸衰竭需要住院治疗的人，插管,和静脉-静脉体外膜氧合（VV-ECMO）。鉴于临床状况的严重程度，同情给予Benralizumab，它靶向IL-5受体，试图。
■抗IL5受体治疗开始五天后，患者拔管,停止ECMO.在降级到呼吸重症监护病房(RICU)后,患者从氧气治疗中断奶，随后出院。
■Benralizumab在改善呼吸衰竭方面表现出快速有效性，从而成功地从VV-ECMO撤机并随后拔管。
■抗IL5受体治疗开始五天后，患者拔管,停止ECMO.在降级到呼吸重症监护病房(RICU)后,患者从氧气治疗中断奶，随后出院。
■Benralizumab在改善呼吸衰竭方面表现出快速有效性，从而成功地从VV-ECMO撤机并随后拔管。
